BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

How Long It Takes to Start a Clinical Trial in 8 APAC Markets, Timed

If you are building a 2027 trial budget this month, you are probably working from a spreadsheet with one row per country and a column headed "start-up". Mo...

October 19, 2026 | News

Mitochondrial-Derived Peptides: What Research Has Shown So Far

Scientists have described eight MDPs: humanin, MOTS-c and six small humanin-like peptides (SHLP1 to SHLP6). Research has focused on different aspects of th...

October 12, 2026 | News

From Academic Discovery to Biopharma Impact: Strengthening Southeast Asia’s Translation Pathway

Universities and public research institutes across the region are advancing research in cancer treatment, cell therapy, biologics and other emerging fields...

October 07, 2026 | Opinion | By Hajjerah TMK Hassan, Director, Discovery and Channels - ASEAN |Cytiva

Biotech Failures 2026: What Did Not Happen in APAC Biopharma

Approvals get counted, deals get ranked, listings get priced. The other half of the year, the programmes that stopped, the applications that came back, the...

October 02, 2026 | Analysis

APAC Biotech IPOs of 2026: Who Listed, What It Raised, Where It Trades Now

How this list was built Scope. Every biotech initial public offering with a first trading day between 1 January and 24 September 2026 on five venu...

September 29, 2026 | Analysis

Every First Approval in APAC, 2026: The Full List

Asia-Pacific’s New Drug Boom: 99 Approvals, 20 World Firsts Somewhere in the second week of January, a BeOne Medicines BCL2 inhibitor called sonroto...

September 23, 2026 | Analysis

The Arbitrage Triangle

METHOD IN BRIEF Flow estimates come from published government statistics and press reporting of official material; no authority in the region publishes in...

September 09, 2026 | Analysis

Where the Longevity Money Actually Goes

METHOD IN BRIEF Window: 1 January to 31 August 2026 for round-level claims, with full-year 2024 and 2025 figures for context. Attribution follows scientif...

September 07, 2026 | Analysis

Nobody Is the Payer

A gerotherapeutic that delays five diseases by three years each would produce savings across five budget lines over thirty years, and a cost that lands in ...

September 04, 2026 | Analysis

Making a Drug People Take for Twenty Years

METHOD IN BRIEF Cost-of-goods figures in this article are reconstructions, not disclosures. No company supplied a cost-of-goods figure and none is...

September 01, 2026 | News

The Accidental Gerotherapeutic

METHOD IN BRIEF Outcome evidence in this article is taken from published trial results and approved label language only. No efficacy or outcome claim is s...

August 31, 2026 | Analysis

The Biological Age Business

On coming 4th September at six in the evening Singapore time, a public consultation will close. It opened on 7 August, it is still open as this is publishe...

August 27, 2026 | Analysis

6 Radiopharmaceutical Programmes and Sites to Watch in APAC

Radioligand therapy is the one modality a region cannot buy its way into late. A vial of lutetium-177 loses half its therapeutic activity in roughly six an...

August 18, 2026 | Analysis

The Sarcopenia Definition Race: The Endpoint Is the Asset

In a category with no approvable indication anywhere in the world, whoever writes the endpoint definition controls who is eligible for a trial, what counts...

August 12, 2026 | Analysis

Stay Connected